NasdaqGS:ADAP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States.


Snowflake Analysis

Excellent balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Adaptimmune Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ADAP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.6%

ADAP

-1.5%

US Biotechs

3.8%

US Market


1 Year Return

216.0%

ADAP

22.1%

US Biotechs

9.7%

US Market

Return vs Industry: ADAP exceeded the US Biotechs industry which returned 22.1% over the past year.

Return vs Market: ADAP exceeded the US Market which returned 9.7% over the past year.


Shareholder returns

ADAPIndustryMarket
7 Day1.6%-1.5%3.8%
30 Day215.1%3.5%11.4%
90 Day222.4%9.0%6.8%
1 Year216.0%216.0%23.3%22.1%12.1%9.7%
3 Year126.8%126.8%26.1%22.1%36.2%27.2%
5 Year-41.7%-41.7%-5.5%-11.0%63.7%45.4%

Price Volatility Vs. Market

How volatile is Adaptimmune Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Adaptimmune Therapeutics undervalued compared to its fair value and its price relative to the market?

44.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ADAP ($11.25) is trading below our estimate of fair value ($20.18)

Significantly Below Fair Value: ADAP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ADAP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ADAP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADAP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ADAP is overvalued based on its PB Ratio (7.9x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Adaptimmune Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-16.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADAP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ADAP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ADAP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ADAP's revenue (56.1% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: ADAP's revenue (56.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ADAP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Adaptimmune Therapeutics performed over the past 5 years?

-27.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ADAP is currently unprofitable.

Growing Profit Margin: ADAP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ADAP is unprofitable, and losses have increased over the past 5 years at a rate of -27% per year.

Accelerating Growth: Unable to compare ADAP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADAP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: ADAP has a negative Return on Equity (-74.14%), as it is currently unprofitable.


Next Steps

Financial Health

How is Adaptimmune Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ADAP's short term assets ($227.8M) exceed its short term liabilities ($29.8M).

Long Term Liabilities: ADAP's short term assets ($227.8M) exceed its long term liabilities ($69.4M).


Debt to Equity History and Analysis

Debt Level: ADAP is debt free.

Reducing Debt: ADAP had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADAP has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ADAP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Adaptimmune Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ADAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ADAP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADAP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADAP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADAP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Ad Rawcliffe (47yo)

0.75

Tenure

US$2,148,256

Compensation

Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune  ...


CEO Compensation Analysis

Compensation vs Market: Ad's total compensation ($USD2.15M) is below average for companies of similar size in the US market ($USD4.76M).

Compensation vs Earnings: Ad's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Adrian Rawcliffe
CEO, Principal Accounting Officer & Director0.75yrUS$2.15m0.0095% $163.7k
Helen Tayton-Martin
Co-Founder & Chief Business Officerno dataUS$1.36m0.16% $2.7m
William Bertrand
Chief Operating Officer3.25yrsUS$1.37m0.010% $172.4k
Gavin Hilary Wood
Chief Financial Officer0.17yrno datano data
Sébastien Desprez
Vice President of Communications & Investor Relationsno datano datano data
Margaret Henry
Head of Public Relations & Company Secretaryno datano datano data
Rafael Amado
President of Research & Development5.25yrsUS$2.60mno data
Lini Pandite
Senior Vice President of Clinical Development5.08yrsno datano data
Trupti Trivedi
Head of Biometrics and Vice President4.75yrsno datano data
P. Dyson
Head of Autoimmune Group4.42yrsno datano data

4.4yrs

Average Tenure

52yo

Average Age

Experienced Management: ADAP's management team is considered experienced (4.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Adrian Rawcliffe
CEO, Principal Accounting Officer & Director0.75yrUS$2.15m0.0095% $163.7k
David Mott
Independent Chairman of the Board of Directors3.42yrsUS$129.79k0.51% $8.7m
James Noble
Non-Executive Director5.5yrsUS$3.12m1.43% $24.7m
Charles Sigal
Independent Non-Executive Director5.33yrsUS$86.69k0.047% $813.0k
Barbara Duncan
Independent Non-Executive Director4yrsUS$70.86kno data
Ali Behbahani
Independent Non-Executive Director5.33yrsUS$86.69kno data
Lawrence Alleva
Independent Non-Executive Director5.25yrsUS$130.30k0.015% $261.1k
Tal Zaks
Independent Non-Executive Director3.58yrsUS$93.36kno data
John Furey
Independent Non-Executive Director1.92yrsUS$88.96kno data

4.0yrs

Average Tenure

54yo

Average Age

Experienced Board: ADAP's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.7%.


Top Shareholders

Company Information

Adaptimmune Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Adaptimmune Therapeutics plc
  • Ticker: ADAP
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.729b
  • Shares outstanding: 153.68m
  • Website: https://www.adaptimmune.com

Number of Employees


Location

  • Adaptimmune Therapeutics plc
  • 60 Jubilee Avenue
  • Milton Park
  • Abingdon
  • Oxfordshire
  • OX14 4RX
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADAPNasdaqGS (Nasdaq Global Select)YesSPONDS ADRUSUSDMay 2015
473ADB (Deutsche Boerse AG)YesSPONDS ADRDEEURMay 2015

Biography

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company’s specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune’s PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/06 05:43
End of Day Share Price2020/06/05 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.